Ebola virus matrix protein VP40 triggers inflammatory responses linked to the ebolavirus virulence

S Satoko Yamaoka (Department of Medicine, Division of Infectious Diseases, Mayo Clinic) Z Zeineb M’Hamdi (Vaccine and Infectious Disease Organization, University of Saskatchewan) L Lin Wang V Vaille A. Swenson (Virology and Gene Therapy Track, Mayo Graduate School of Biomedical Sciences) K Kristin L. McNally (Laboratory of Virology, Rocky Mountain Laboratories, National Institute of Allergy and Infectious Diseases, National Institutes of Health) S Shao-Chia Lu R Reema Singh (Vaccine and Infectious Disease Organization, University of Saskatchewan) S Stephanie L. Saundh (Vaccine and Infectious Disease Organization, University of Saskatchewan) B Brady N. Zell (Virology and Gene Therapy Track, Mayo Graduate School of Biomedical Sciences) S Sonja M. Best (Laboratory of Virology, Rocky Mountain Laboratories, National Institute of Allergy and Infectious Diseases, National Institutes of Health) M Michael A. Barry A Angela L. Rasmussen (Vaccine and Infectious Disease Organization, University of Saskatchewan) H Hideki Ebihara (Department of Virology 1, National Institute of Infectious Diseases, Japan Institute for Health Security)

Abstract

Uncontrolled systemic inflammatory responses are a critical pathological feature of fatal Ebola virus (EBOV) infection. While some inflammatory responses may originate from mononuclear phagocytes (MNPs), nonimmune cells vastly outnumber MNPs and may be an important source of inflammation. Here, we demonstrated that highly virulent EBOV induced a high and sustained pro-inflammatory response compared to less virulent ebolaviruses in non-MNPs through TLR4-independent NF-κB activation. We identified the EBOV matrix protein VP40 as a potent activator of NF-κB in non-MNPs, whose intrinsic inflammatory activation ability is higher than VP40 proteins from less virulent ebolaviruses. This suggests that VP40 is a virulence determinant inducing distinct degrees of pro-inflammatory responses among ebolaviruses. Mechanistically, VP40 activated the NF-κB signaling pathway, primarily via TNFR1 using a ligand-independent mechanism. These findings reveal mechanisms that may drive systemic inflammation and promote EBOV pathogenesis, suggesting potential therapeutic strategies to mitigate immune dysregulation in severe EBOV infections.

Article Details

Volume / Issue Vol. 123, Issue 1
Published January 06, 2026
ISSN 0027-8424
Publisher National Academy of Sciences

Authors (13)

S

Satoko Yamaoka

Department of Medicine, Division of Infectious Diseases, Mayo Clinic

Z

Zeineb M’Hamdi

Vaccine and Infectious Disease Organization, University of Saskatchewan

L

Lin Wang

V

Vaille A. Swenson

Virology and Gene Therapy Track, Mayo Graduate School of Biomedical Sciences

K

Kristin L. McNally

Laboratory of Virology, Rocky Mountain Laboratories, National Institute of Allergy and Infectious Diseases, National Institutes of Health

S

Shao-Chia Lu

R

Reema Singh

Vaccine and Infectious Disease Organization, University of Saskatchewan

S

Stephanie L. Saundh

Vaccine and Infectious Disease Organization, University of Saskatchewan

B

Brady N. Zell

Virology and Gene Therapy Track, Mayo Graduate School of Biomedical Sciences

S

Sonja M. Best

Laboratory of Virology, Rocky Mountain Laboratories, National Institute of Allergy and Infectious Diseases, National Institutes of Health

M

Michael A. Barry

A

Angela L. Rasmussen

Vaccine and Infectious Disease Organization, University of Saskatchewan

H

Hideki Ebihara

Department of Virology 1, National Institute of Infectious Diseases, Japan Institute for Health Security